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ABSTRACT 
Background 
Sulphated saccharides, primarily sucralfate, have previously been indicated 
for the treatment of gastric and duodenal ulcers. In radio-labelled form, sucralfate 
has also been used as a diagnostic agent for the imaging of gastrointestinal 
mucosa, since the substance binds selectively to ulcerated areas in the stomach 
and upper small intestine. It has been found that sucralfate exerts an anti-
inflammatory effect when applied topically to the skin and to mucosal surfaces, 
and that sucralfate exerts a beneficial effect on wounds when applied topically on 
epithelial surfaces outside the digestive tract. Accordingly, the present study 
relates to the use of sucralfate for the preparation of a medication for topical 
application over the skin or to any nongastrointestinal surface. Although the 
evidence is not yet conclusive the clinical evidence tends to support the anti-
inflammatory effect and wound healing effect of sucralfate. 
Objectives of the study 
• To compare the efficacy of topical sucralfate with that of a control group 
using 
• conventional dressings, in the healing of diabetic ulcers in terms of: 
Number of days needed for healing 
• To study the healing properties of sucralfate in management of 
nongastrointestinal wounds 
• Rate of reduction in mean ulcer surface area 
• To assess the effect of topical sucralfate on bacterial load by comparing the 
culture and sensitivity of wound swabs before and after application of 
sucralfate 
Methodology: 
This was a comparative study conducted at Tirunelveli Medical College 
Hospital,Tirunelveli.Total of 100 patients were studied. They were separated into 
2 groups through computerized randomization. Patients in Control group were 
treated with conventional dressing and patients in Study group were treated with 
sucralfate dressing and watched for the wound size reduction. 
Results: 
The study group patients showed higher reduction in wound size of about 
40.87%as against 15.63% of the control group with P value < 0.001. 
Conclusion 
Topical application of sucralfate once daily significantly increases 
incidence of 
wound healing  and reduce the time required for healing in diabetic ulcers. 
Key words 
Sucralfate, Topical application, Diabetic foot ulcer 
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Introduction 
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INTRODUCTION 
 
In this millennium where man has succeeded in deciphering human genetic 
code, the issue of management chronic wound still continues an enigmatic 
challenge. Diabetic ulcers, particularly non healing types, are one of the most 
common surgical issues. From time immemorial doctors are trying different 
methods to treat these kind of ulcers. 
The difficulty in a chronic ulcer, is its refusal to heal, whatever 
management given, especially diabetic ulcers. 
The notion that ulcers should be kept dry, although still held by a 
considerable number of clinicians, is steadily losing ground. We now know that 
ulcers reepithelialize much faster or develop granulation tissue faster when treated 
with dressings which allow moist wound healing. We recognize that occluding 
ulcers does not lead to infection. 
A ulcer care revolution is currently in the making. Many techniques have 
been tried over the centuries to heal diabetic leg ulcers. Although wound dressings 
have been used for at least two millennia, there exists no ideal dressing. Surgical 
dressing of  wounds depends on tradition, training and the surgeons own 
philosophy. 
During the last 2 ½  decades a wide range of innovative dressings have 
been introduced. People have tried various non-conventional topical therapies in 
wound healing, such as Aloe vera, Benzoyl peroxide, collagen, gentian violet, 
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impregnated gauze, topical phenytoin, mercurochrome, oxygen therapy, sugar and 
vinegar. 
Studies have also proven that topical sucralfate promotes healing of 
decubitus ulcers, venous stasis ulcers, traumatic wounds, burns, trophic ulcers and 
was seen to be superior management of diabetic ulcers. 
Sucralfate, an oral gastrointestinal medication primarily indicated for the 
treatment of active duodenal ulcers, is also used for the treating gastroesophageal 
reflux disease (GERD) and stress ulcers. 
It shows potential utility in the healing of skin wounds. Sucralfate induces 
proliferation of dermal fibroblasts and keratinocytes. It also enhances 
prostaglandin E2 synthesis in basal keratinocytes, enhances interleukin-1-
stimulated interleukin-6 release from fibroblasts. When applied to full-thickness 
wounds daily, sucralfate increased the thickness of granulation tissue. It also 
promotes rapid epithelialisation of 2nd degree burns 
A series of studies in animals has shown that application of sucralfate to a 
wound enhances the wound repair process. Sucralfate has been demonstrated in 
preclinical studies to promote the granulation tissue formation and thus promoting 
cutaneous ulcer healing. 
Various human cellular studies have definitely established the fact that for 
diabetic ulcers which are resistant to conventional treatment, topically applied 
sucralfate is a new pharmacologically active therapy Various studies showed the 
efficacy of sucralfate, that is complete healing of the wound, and the reducing the 
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size of the wound. Sucralfate stimulates granulation tissue and promotes 
cutaneous ulcer healing. 
In view of other studies regarding the efficacy of sucralfate in diabetic 
ulcers, we undertook this study to know whether sucralfate applied topically over 
the diabetic ulcers reduces the size of the wound effectively compared to normal 
saline dressing( conventional treatment) 
  
 
 
 
 
 
 
 
 
 
 
Aim and Objective 
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AIM AND OBJECTIVE OF THE STUDY 
 
• To compare the efficacy of topical sucralfate with that of a control group 
using 
conventional dressings, in the healing of diabetic ulcers in terms of: 
• Number of days needed for healing 
• To study the healing properties of sucralfate in management of 
nongastrointestinal wounds 
• Rate of reduction in mean ulcer surface area 
• To assess the effect of topical sucralfate on bacterial load by comparing the 
culture and sensitivity of wound swabs before and after application of 
sucralfate 
• From January 2014 to July 2015 are taken for study 
• At Tirunelveli medical college, Department of surgery 
 
  
 
 
 
 
 
 
 
 
 
 
Review of Literature 
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REVIEW OF LITERATURE 
 
HISTORICAL BACKGROUND OF WOUND HEALING 
• The treatment and healing of wounds are the oldest topics discussed in the 
medical literature and probably earliest problems of human race. 
• Early surgeons like Ambrose, Pare, John Hunter, & Sir James Paget have 
given some scientific knowledge to their handling of wounds, particularly 
those resulted from war. 
• Halsted was intensely interested in wound healing process. 
• In the early 1900’s Carrel & his associates made investigations with the 
scientific approach to wound healing. Later Carrel (1916), Harvey & 
Howe’s (1930), studied incised wounds & contributed to the knowledge of 
wound healing. 
• There is a saying; “If there were no regeneration, there would be no life; if 
everything regenerated, then, there would be no death”. 
• The earliest medical writings deal extensively with wound care. Seven of 
the 48 case reports included in the Edwin Smith Papyrus (1700 BC) 
describe wounds and their management. 
• Empirically, in Egypt, Greece, India and Europe, the physicians developed 
gentle methods of treating wounds by removing foreign bodies, suturing, 
covering wounds with clean materials, and protecting injured tissues from 
corrosive agents 
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• More than 4000 years ago, the theory of the "three healing gestures" was 
formed,with earliest writing recorded on a clay tablet from 2200 BC. 
The tablet describes the three gestures as: 
• wound washing 
• plasters over the wound 
• application of bandage over the wound 
• These gestures evolving into varying forms of today’s same basic themes. 
The Greeks belief of dry healing came from Hippocrates, at a time when 
the only function of dressings was thought to be the protection of the 
wound from injury. 
• During the fourteenth century, with the widespread use of gunpowder and 
the increasing frequency of bullet wounds, there was an increased need for 
surgeons assuming an aggressive posture, which was often done at the 
expense of aseptic precautions. Examples included applications of burning 
oil, scalding water, wine, turpentine, feathers, sugar, clay, bismuth, milk of 
magnesia to wounds. However, none of these have proven efficacy leased 
on sound scientific studies. 
• The modern era of gentle wound care started in the mid-sixteenth century, 
when Ambroise Pare, the great French army surgeon, who during the 
Battle of Villaine, applied milder agents like digestive solution of egg yolk, 
rose oil, honey and turpentine to amputation stumps with dramatic results. 
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• John Hunter, William Stewart Halsted, Alexis Carrel and many other great 
clinical biologists demonstrated that minimizing tissue injury produces 
rapid and effective healing leading to the "minimal interference" concept of 
wound care. If the surgeon can remove all impediments, normal wound 
healing process will produce the best possible result. 
• Joseph Lister advocated cleanliness in the hospital, the frequent use of soap 
and water on wounds and carbolic acid dressings of contaminated wounds. 
Later Semmelweis, Ehrlich, Fleming, and Florey also realized that bacteria 
were pathogens. Control of bacteria by asepsis, antiseptics and 
antimicrobials heralded a new era in wound management. 
• Finally it is apt to say that advances of the previous decades are only a 
prelude to the changes in wound care management that will occur in the 
coming decades. 
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DIABETES MELLITUS 
Definition: 
“Diabetes mellitus is characterized by chronic hyperglycemia with 
disturbances 
of carbohydrate, fat, and protein metabolism resulting from defects in insulin 
secretion, insulin action, or both”. 
Hyperglycemias may be due to the following etiological factors: 
¾ Reduced insulin secretion 
¾ Decreased glucose utilization 
¾ Increased glucose production 
Classification 
TYPE I 
Type Pathology 
I A : Autoimmune beta cell destruction Insulin Deficiency 
I B : Develop insulin deficiency by unknown mechanism causing destructive 
process of beta cells Lack immunologic markers 
Type II 
Is characterized by :- 
¾ Impaired insulin secretion 
¾ Insulin resistance 
¾ Excessive glucose formation 
Type-2 DM is preceded by a period of abnormal glucose haemostasis 
classified as 
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¾ Impaired glucose tolerance (IGT) 
¾ Impaired fasting glucose (IFG) 
Diagnosis  
Diagnostic criteria for Diabetes Mellitus type2( WHO & National diabetic 
Data Group): 
¾ RBS ≥200 mgs / dL Or ≥11.1 m mol / L with symptoms of DM 
(Polyuria,Polydipsia, Polyphagia, Weight loss) 
¾ FBS ≥126 mgs / dL or ≥ 7.0 m mol / L 
¾ 2 Hr Plasma Glucose (During Oral GTT) ≥ 200 mgs / dL or ≥11.1 m 
mol/L  
¾ Strong co-relation b/w ↑ FPG & ↑ HbA1c concentration but 
currently notrecommended for the diagnosis of DM. 
 
Table 3.1: Diagnosis of Diabetes Mellitus 
Terms Definition 
 
Random Blood Glucose 
(RBS) 
Blood Glucose levels without regard to time since 
last 
Meal 
Fasting Blood Glucose 
(FBS) 
Blood Glucose levels when there is no caloric 
intake forpast 8 Hrs 
2 Hr Plasma Glucose 
(During Oral GTT) 
 
75gm of glucose(anhydrous form) mixed with 
water. 
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Chronic Complications of DM 
 Mortality and morbidity asso with T2DM are mainly due to the chronic 
complications of DM 
Fig. 2.1: Chronic Complications of DM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Sensory & motor 
(Mono & Poly 
neuropathy) 
 Autonomic 
Eye disease Neuropathy Nephropathy 
 Retinopathy (Non 
–Proliferative / 
Proliferative) 
 Macular oedema 
Microvascular 
Complications 
Macrovascular 
complications 
CAD/ IHD Peripheral vascular 
disease 
Cerebro vascular 
abnormality 
Other complications 
Gastro-intestinal ( delayed/increased gastric emptying ) 
Genitor-urinary (Uropathy / Sexual dysfunction) 
Dermatological 
Infections 
Ophthalmological (Cataracts and Glaucoma) 
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• With the increase in duration of the disease(hyperglycaemic state), the is 
associated increase in risk of chronic complications.  
• At the time of diagnosis, the patient may present with complications 
because of the long asymptomatic periods of hyperglycemia. 
• In both type 1 and type 2 diabetes mellitus, microvascular complications 
are seen as a result of chronic hyperglycemia.  
• Many clinical trials shows that there is significant prevention/delay in 
retinopathy, neuropathy and nephropathy if chronic hyperglycaemic phase 
is reduced. 
• In type 2 DM patients, there is two to four fold increase in incidence of 
coronary heart disease mortality. 
• The above  events have a positive correlation with FBS and PPBS glucose 
levels as well as with the Hb A 1 C. 
• Macrovascular complications are also related to Dyslipidemia and 
increased blood pressure  
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Complications - mechanism 
A hypothesis proposes that leading to : 
Fig. 2.2: Mechanisms of Complication of Diabetes Mellitus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hyperglycemia 
 
Alteration of functions by hexosamine pathway may be by 
Glycosylation of proteins such as endothelial nitric oxide synthase 
By changes in gene expression of transforming growth factor β (TGF- β) 
Plasminogen activator inhibitor-l (PAI-l). 
Production of fructose-6-phoshate, Production of proteoglycans and a 
substrate for O-linked glycosylation. 
     Increase  hexosamine pathway influx 
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Figure showing - Possible molecular mechanism of diabetes-related complications 
AGEs : Advanced glycosylation end products 
PKC : Protein kinase – C 
DAG : Diacylglycerol 
c PLA 2 : Phospholipase A2 
eNOS : Endothelial Nitric Oxide Synthase 
Hyperglycemia 
↑intracellular glucose 
↑AGEs ↑ Sorbitol ↑DAG ↑ Fructose-
6-P
Abnormal 
protein 
function 
↑Circulating 
AGEs 
Alteration 
in redox 
potentials 
ROS
Altered 
cell 
PKC 
activation 
Complication
s of diabetes 
Growth 
Factors 
↑PAI-
1,
Altered 
gene 
expres
Altered 
enzyme 
function 
(cPLA2) 
NOS
↑flux in 
hexosamine 
pathway
Renal, 
Vascular, 
Connective 
tissue effects 
Cytokines, 
Altered cell 
function 
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ROS : Reactive oxygen species 
PAI-l : Plasminogen activator inhibitor-l 
Neuropathy And Diabetes Mellitus  
¾ The prevalence of diabetic neuropathy in patients with type 2 diabetes is 32 
percent overall and more than 50 percent in patients over 60 years of 
age.1,2 
¾ Diabetic neuropathy have a positive correlation with the disease duration 
and control of hyperglycemia in type1 & 2 DM. 
¾ May manifest as Polyneuropathy/ Mono-neuropathy/Autonomic 
Neuropathy 
¾ All the nerve fibers (including myleinated and unmyelinated) are affected. 
¾ Diabetic neuropathy have similar clinical features when comapering with 
other neuropathical diseases, therefore all other possible causes should be 
excluded before making a diagnosis 
Poly-neuropathy / Mono-neuropathy : 
¾ The most common form of diabetic neuropathy is distal symmetric 
¾ polyneuropathy. 
¾ It presents as: 
1. Distal sensory loss - most frequent presentation 
2. Hyperesthesia 
3. Paresthesia 
4. Dysesthesia  
15 
 
¾ Symptoms includes a sensation of following, which begins in the 
feet & spreads proximally. 
1. Numbness, 
2. Tingling 
3. Sharpness 
4. Burning 
As neuropathy progresses,any of the following symptoms may develop 
¾ Physical examination reveals 
1. Loss of sensation 
2. Ankle reflexes lost 
3. Position sense abnormality. 
¾ Pain usually rest pain may be present in the lower limbs, which may 
increase at night. 
¾ With the progression of the disease, there will be decrease in the 
intensity of the pain and eventually it disappears. But in the 
extremities, sensory loss may persists. 
¾ In some patients, with the improvement in glycemic status, 
development of neuropathic pain is seen. 
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Diabetic Neuropathy : 
It may be accompanied by - Motor weakness 
 
 
 
 
 
 
 
 
Treatment of diabetic neuropathy : 
• Nerve conduction velocity will be better if the glycemic control of the 
patient is improved.but there won’t be any improvement in neuropathic 
symptoms. 
• Alcohol and other neuro toxins should be avoided, vitamins for possible 
deficiencies (BI2, B6, folate) should be supplemented 
• Treatment of symptoms. 
• After the 1st year of the diabetic neuropathy, there will be substantial 
decrease in pain, due to the progressive neuronal damage from DM. 
Therefore analgesics may be discontinued after this. 
• Chronic, painful diabetic retinopathy – treatment is usually difficult, but 
may respond to 
1. Tricyclic antidepressants - Amitryptiline, desipramine, nortriptyline 
Definition-“It is a syndrome characterized by severe 
disabling pain in the distribution of one or more nerve root” 
femoral nerve  involvement. Also lumbar plexusIntercostals or truncal radiculopathy
Pain in hip & or thigh& may be asso. with hip flexors 
or extensors weakness   
       Pain over nerve root 
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2. Gabapentin 
3. NSAIDs (Avoid in renal dysfunctions) 
4. Others (Mexilitine, Phenytoin, Carbamazepine, Capsaicin cream) 
The patient should be reffered to any pain management clinic.. 
Lower Extremity Complications 
• In diabetic patients, the major source of morbidity is ulcers over the foot 
and infetions over that region. 
• Increased occurrence of lower limb complications in DM is due to 
interaction of may pathogenic factors 
¾ Neuropathy 
¾ Abnormal foot biomechanics 
¾ Peripheral arterial disease 
¾ Poor wound healing. 
Neuropathy: 
75% of patients having foot ulcers develop neuropathy. 
Peripheral sensory neuropathy: 
 Due to this, patients will be having repeated minor injuries over the feet, 
leading to defect in normal protective mechanisms. These happen without the 
knowledge of the patients. 
Motor and sensory neuropathy: 
May cause abnormality in mechanism of foot muscles and may also cause 
change in structure of the foot  (hammer toe, claw toe deformity, prominent 
metatarsal heads, Charcot joint) 
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Autonomic neuropathy : 
Lead to dry skin, fissure etc. as a result of anhydrosis and blood flow 
alterations. 
Peripheral arterial disease and poor wound healing : 
 Cause defective healing of minor injuries in skin, leading to enlargement of 
the wound and super added infection 
Disordered proprioception : 
Callus formation and ulceration is formed due to abnormal weight bearing 
while walking and standing. 
Approximately 15% of individuals with DM develop a foot ulcer, and a 
significant subset will ultimately undergo amputation (14 to 24%) risk with that 
ulcer or subsequent ulceration. 
VASCULAR CHANGES IN DIABETES 
1. Atherosclerosis: Chronic inflammatory process that can be converted into 
acute clinical event by plaque rupture. 
Development of atherosclerosis is accelerated in DM leading to increased 
morbidity and mortality. All the large vessels are involved in this process and 
clinical manifestations are apparent as a result of atherosclerotic narrowing and 
thrombosis of coronary, cerebral and leg vessels 
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І Lipoproteins pathogenesis: 
Fig 2.3 Pathophysiology Diabetic Vasculopathy 
Diabetes Mellitus 
 
LDL transport across vessel wall 
 
Trapped by cellular matrix of sub endothelial space 
 
Oxidation 
 
Chemotactic factors released 
 
Monocyte chemo-attractant proteoin 
 
Further oxidation of LDL 
 
Cytotoxic LDL 
 
Not recognized by receptor 
 
Taken up by macrophages 
 
Formation of foam cells 
 
‘Attract smooth muscles from media to intima 
 
Fibro-fatty plaques 
 
Narrowing of vessels 
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П Endothelium: 
a. Nitric oxide, (NO): (EDRF-Endothelium derived relaxing factor) 
Nitric oxide, (NO) 
 
 
 
 
 
 
b. Prostacyclin (PGI2) 
PGI2 
 
Potent vasodilator also inhibits 
Platelet adhesion & aggression 
 
Prostacyclin stimulating factor 
(Present in human arterial smooth muscle) 
 
↓se in Diabetics & arterial wall of patients with old MI 
 
c Thromboxane A2(TX-A2):>>>>Vasoconstrictor- Counteracts effect of N.O 
↑sed levels found in DM, HTN & hyperlipidemia 
. 
Nitric oxide, (NO) 
↑se Collagen synthesis 
Accumulation in kidney 
Nephropathy Neuropathy 
Regulates polyol 
pathway
Changes in retinal 
circulation 
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d Endothelin::>>>>Vasoconstrictor 
↑sed levels found in DM around 3.5 times 
 
Fig 2.4 Pathogenesis of Diabetic Ulcers. 
 
Diabetes Mellitus 
Neuropathy & limited joint mobility 
 
Atrophy of intrinsic muscles & clawing 
 
Pressure transfer from heel & toes to metatarsal heads 
 
No redistribution of pressure 
 
         Ulceration                       
Predisposing factors for ulceration:  
1) Limited joint mobility. 
2) Peripheral neuropathy. 
3) High plantar pressure. 
4) Vascular diseases. 
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Biomechanics of diabetic foot  
Gait cycle: 
1. Stance phase  
2. Swing phase                     
Fig 2.5 Biomechanics of Diabetic Foot 
 
Stance phase 
 
Contact  phase  mid stance phase      propulsive phase 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To toe off 
opposite 
limb 
Opposite 
toe off 
forefoot 
loading and 
heel lift 
Passive lift 
off 
Active 
propulsion 
Plantar 
flexion 
Dorsiflexion 
(max 
pressure on 
forefoot) 
Heel lift off supporting 
side & ends with 
opposite side heel 
strike 
Opposite heel 
contact &terminates 
with supporting side 
toe off 
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Changes in foot caused by diabetes 
1. Peripheral neuropathy 
A. Dryness of skin 
B. Callus formation 
2. High pressure at bony prominences 
↓se plantar tissue thickness 
 
Weak intrinsic muscles of foot 
 
Imbalances of flexors & extensors causing clawing of foot 
 
Pulling away fat padding from metatarsal heads 
 
3 Limited joint mobility  
Unknown etiology 
Collagen abnormality 
Thickening of skin, tendons & joint capsules 
Decreased tissue flexibility 
Increased plantar pressure 
4 Trauma  
 
Trauma 
 
Intrinsic        Extrinsic 
 
Repetitive stress from high pressure / Callus    Ill-fitting footwear 
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       Fig 2.6 Causation of ulceration 
Pressure 
 
 
Duration    ↑se magnitude   Repetitions of pressure 
 
 
 
Relatively low  High pressure  Foot slap   Mechanicalfatigue 
Pressure for   acting for short     of tissues 
longer periods  duration 
 
Weak dorsiflexion 
 
Ischemia         Loss of tissue 
↓se deceleration   integrity 
of forefoot 
 
 
Cell death          Breakdown 
 
 
Rapid strike due to 
Wound      ↑se velocity  
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CLASSIFICATION OF DIABETIC FOOT ULCERS. 
The six grade Wagne- Meggit classification, which has been used for 
decades, classifies wounds by the depth of ulceration and extent of gangrene. The 
PEDIS classification (by International Working Group on Diabetic Foot) 
¾ Perfusion (arterial supply) 
¾ Extent (area) 
¾ Depth 
¾ Infection 
¾ Sensation 
WOUND DRESSING IN DIABETIC FOOT 
In the management of diabetic foot, the main aspect is the dressing of the 
wound and wound managment. For the limb to be salvaged, proper scientific, cost 
effective method should be used for dressing the wound. The various functions of 
the dressings are: 
¾ wound isolation 
¾ edema limitation/reduction 
¾ pain reduction 
¾ exchange of gases from blood to tissue should improve. 
¾ Inflammation should be limited 
¾ exudates should be absorbed 
¾ bacterial growth should not be promoted. 
¾ contamination and dessication should be prevented 
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All the dressings can be classified as primary or secondary. Primary 
dressing is the one, which is in direct contact with the wound. Secondary dressing 
is of the material, which holds the primary dressing in place. It has function of 
compression, occlusion and additional protection. 
Diabetic Foot Disease: An Understanding of The Disease: 
Pathophysiology: 
 Knowledge of the pathophysiologic changes caused by diabetes Mellitus is 
essential for understanding and treatment of diabetic foot problems. Sustained 
hyperglycemia, neuropathy, infections and ischemia are the principal pathogenic 
factors. 
Neuropathy: 
Diabetic patients develop sensory, motor and autonomic neuropathy. The 
neuropathic foot is characteristically healthy. It is well nourished, hair will be 
present, has good dorsalis pedis pulsations and posterior tibial pulsation, has a 
high arch. Callus formation common on pressure points over the soles or toes, and 
sweating may be there. This shows lumbar sympathetic activity. Over the soles, 
thick calluses may act as foreign bodies and may lead to bruising of the 
subcutaneous tissues along with extravasation of blood and serum through the 
capillaries. This acts a culture medium for local bacteria to grow and leading to an 
abscess. The condition may not be known by the patient because of 
anesthesiacaused by the neuropathy and can expand without being detected till the 
patient develops generalized infection or the problem is noticed by it's foul smell. 
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Sometimes the overlying callus may be so hard that the infection can easily 
involve the joint capsule lying below or the metatarsal head below than the callus 
itself. Thus osteomyelitis associated with calluses can be explained and 
understood. The same process may occur over the top of hammer toes or in 
association with the deformed and collapsed bones and joints seen along with 
Neuro-osteoarthropathy / Charcot's foot. 
Vasculopathy: 
Both the Microvascular and Macrovascular disease is present in diabetics. 
Atherosclerosis is speeded up in diabetics. Infrageniculate vessels (Posterior 
tibial, Anterior tibial, peroneal vessels) are affected severely. Perfusion is 
decreased due to occlusive disease withmicrocirculatory impairment of cellular 
exchange. 
Ischemic foot is characteristically scaly dry atrophic and hairless, and 
undernourished. It is cold on touch. The nails are found to be thick and overgrown 
alongwith dry scales under the nail itself. Such ischemic feet usually have a small 
infection behind a nail or in the depth of a fissure. The ischemic foot may have 
small flat, dry atrophic ulcers with full thickness skin necrosis in the centre with a 
rim of erythema surrounding the ulcer. Wet gangrene is seen when a higher vessel 
in the thigh or calfbecomes suddenly occluded. The tissues are still wet and the 
impending gangrene is manifested by pallor, then rubor, and lastly the blistered 
skin withunderlying blue black tissue shining through. Only the ischemic foot has 
these features, and usually the flow into the patent major vessels is not enough or 
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notin time to revive the injured tissues. Therefore higher amputationsare 
necessary. 
Diabetic Angiopathy is classified in to 2 types: 
1. Macro Angiopathy 
• Atherosclerosis - Characterized by formation of atheromatous plaque in 
vessel wall leading to thrombus formation. 
• Monckeberg's Sclerosis / Medial calcific sclerosis- Characterized 
bycalcification of  media of mascular artery 
• Intimal fibrosis -  a part of normal aging process. 
2. Microangiopathy 
Small vessel disease comprises of changes in arterioles and capillaries. 
Occlusion of these capillaries leads to patchy areas of gangrene. The capillaries 
are a common site of diabetic microangiopathy. Homogenous periodic Acid 
Schiff positive thickening of  capillary wall is considered as the hallmark of 
diabetic microangiopathy because of basement membrane thickening. 
Banson and Lacy in their studies involving 18 diabetic & 17 non diabetics, 
foundthat capillary basement membrane thickened in 88% of the Small vessel 
disease consists ofchanges in arterioles and capillaries. Occlusion of these 
capillaries results to patchyarea of gangrene.  
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Infections: 
Infection affects diabetic control. Uncontrolled diabetes causes infection 
because hyperglycemia at wound site that forms nidus for bacterial flora to grow. 
An abscess or cellulitis may produce hyperglycemia, conversely, hyperglycemia 
may affect the healing of abscess. 
Mild infections are commonly due to surface organisms like 
staphylococcus andstreptococcus. Severe infections are polymicrobial that 
includes aerobic gram +ve, anaerobic gram negative rods like (E-Coli, Klebsiella, 
Pseudomonas and Proteus) and anaerobes. Identification using cultures and 
appropriate antibiotics is necessary for controlling infections. When infectious 
process dissects deep in to the soft tissue and enters the periosteum, osteomyelitis 
results. In acute stages of osteomyelitis, the process is a suppurative one. There is 
necrosis of both cortical and cancellous bone with formation of the sequestrum. 
Later chronic osteomylitis develops. 
Guidelines In The Examination of The Diabetic Leg And Foot: 
History: It isimportant to start by checking patients diabetic history. A long 
history of insulin dependent diabetes is often associated with a higher incidence of 
neuropathy, retinopathy and also nephropathy called the "Diabetic triopathy". 
Severe triopathy is thought to be due to secondary to basement membrane 
thickening and in patients who have this, the wound healing appears to be 
delayed. This is particularly true in those patients with renal failure. Consideration 
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of patient’s renal function is also important in deciding whether they are 
candidates for arteriography for further evaluation of arterial insufficiency. 
Hypertension, tobacco consumption, and Hypercholesterolemia are also 
important factors in the development of arterial insufficiency. Severe cardiac 
disease may be contraindication for aggressive management of the diabetic foot 
problems. 
Patient's presenting problem discussed in detail. If the patient describes a 
rapidly enlarging lesion asso. with drainage or swelling, perhaps with red lines 
extendingupto the leg and fever or chills, then infection is very likely. 
The classic distal polyneuropathy seen in diabetic patients may not only 
cause lesions on its own, but may also mask the symptoms of infection and 
arterial insufficiency and may lead to the development of painless ulcer over a 
pressure point. 
Patients may complain of pain, burning sensation of feet, that the feet feel 
cold or feel as encased in concrete or of the sensation of walking on a glass. 
Sometimespatient may describes knife like shooting pains up the legs, usually 
both legs are involved and this may help in distinguishing neuropathic from 
ischemic pain. The history of ischemia is usually present in patients with diabetic 
foot lesion, although these symptoms may be masked by presence of neuropathy. 
A history of cardiac or carotid disease would definitely make the presence of 
peripheral vascular disease more likely. Claudication pain or pain in muscle 
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groups on exercise is the usual presenting symptom of peripheral vascular 
insufficiency. 
Occasionally, particularly in smokers, inflow disease is responsible for 
ischemia, and then buttock and thigh claudication may be their presenting 
symptom. This is known as leriche syndrome due to obstruction of the aortoiliac 
vessels, may be asso. with impotence in men. 
Physical Examination: 
It is helpful to start examination away from the area of interest. The 
carotids should be checked for presence bruits and the presence of pulses in the 
arm. Atrial fibrillation as a possible source of embolisation can be noted. The 
abdomen should be thoroughly examined for an abdominal aortic aneurysm, 
which may also be a source of distal emboli. 
Assessment of Diabetic foot: 
Includes identification of: 
A. . Infection 
B. Vasculopathy 
C. Osteopathy 
D. Neuropathy 
The feet should be looked for 
o Dry skin, cracks, fissures 
o Ulcers, cavity, sinuses 
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o Calluses, hyperkeratosis 
o Infection 
o Gangrene. 
o Foot deformity 
A. Neurologic Examination to assess the sensory and motor disturbances: 
o Monofilament testing 
o Vibration testing using tuning fork 
o Tendon reflexes and also pain 
B. Vascularity is assessed by examination of the: 
o Distal pulses 
o Transcutaneous oxygen saturation  
o Ankle brachial pressure index 
o Duplex arterial study. 
C. Osteomyelitis is assessed by the X - ray examination of  foot 
D. Infection is assessed whether superficial or deep. 
It is usually common to have all three processes occurring at the same time. 
Thus an infected neuropathic lesion seen in a patient with poor circulation is not 
unusual. Significantly neuropathy may hide the signs and symptoms of ischemia, 
and the resultant failure to diagnose the underlying ischemia may result in 
mistreatments. Severe neuropathy may result in a pain free foot that is auto 
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sympathectomised and thus, warm, but at the same time, severely ischemic. A 
minor procedure on such a foot may result in gangrene. 
Table no: 3.2 Grading of Diabetic foot: Wegner's Classification of diabetic 
foot. 
Grade Clinical features 
Grade 0 Normal foot with variable degree of neuropathy. Joint deformity, 
foot 
at risk. 
Grade 1 Superficial ulcer, cellulites 
Grade 2 Uncomplicated deep ulcer 
Grade 3 Complicated deep ulcer, deep infections, osteomyelitis 
Grade 4 Limited necrotizing gangrene 
Grade 5 Extensive gangrene 
 
The Diabetic Foot: Medical and Surgical Management: 
A. Baseline Approach in Managing the Acute Problem of the Diabetic Foot: 
1. Appraise problem 
o Careful inspection with emphasis on web spaces and back of heels. 
o Record pulses, venous filling time, rubor 
o Record sensation. 
2. Describe lesion 
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3. Describe Necrotic tissue, probe sinuses with sterile probe to determine the 
extent of disease. 
4. Culture pus for aerobic and anaerobic organisms 
5. Begin broad spectrum antibiotic until appropriate antibiotics can be given 
according to culture and sensitivity. 
6. Medical Management of Diabetes - Blood sugar monitoring and antidiabetic 
measures to achieve good glycemic control, Doppler study of vessels. 
7. X - ray both feet to exclude osteomyelitis. 
8. No weight bearing (Hospitalize with absolute bed rest when indicated. 
Crutches or walker when feasible.) 
9. Surgical Management of the Problem 
¾ No soaks 
¾ Antibiotics 
¾ Medical Management of diabetes 
¾ Dressing change atleast once daily. 
¾ Surgical debridement, frequently if necessary. 
¾ Consideration for possible arterial reconstruction 
¾ Drainage or open amputation. 
10. Rehabilitation 
¾ Podiatrist for patient education, preventive maintenance, orthotics, healing 
sandals and special shoes. 
¾ Nutritionist to advice on diet needs. 
¾ Surgeon to ensure proper wound healing and proper prosthetics 
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¾ Physician to make final decision about diabetes management. 
¾ Psychiatrist to return to normal activity. 
PREVENTION IS BETTER THAN CURE: 
Prevention of ulceration and recurrence once ulceration has occurred are 
the ultimate goals of any modern team approach to the diabetic foot. 
Wagner's Grade O: Foot are the patients who are potentially "at risk" to develop 
ulcer or infection due to varying degree of neuropathy and joint deformities. They 
need regular* assessment annually for neuropathy and vascular status. Hence the 
role of proper footwear and hygiene cannot be overemphasized. The diabetic 
patient and his family must establish a routine for daily foot and shoe inspection 
and hygiene. Every patient must be taught to shake his shoes at and inspect them 
prior to wearing. Proper hygiene must become a religion. Washing the feet 
everyday with mild < soap and rinsing and drying thoroughly especially between 
the toes are adviced. 
The physician or health care provider must always set the example. 
Controlling blood glucose, weight, and blood pressure; eliminating smoking; 
encouraging daily exercises are important. Periodical neurological and vascular 
examinations are important. Early recognition and prompt reporting of a problem 
are encouraged. 
Principles of Medical Management: 
¾ Pus from ulcers sent for culture and sensitivity. 
¾ Careful monitoring of the blood glucose levels. 
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¾ Appropriate antidiabetic measures either insulin preparations or oral 
hypoglycemic drugs. 
¾ Broad spectrum antibiotics to be started at the onset and change over to 
other antibiotics depending on the culture and sensitivity report. 
¾ Patients with limb threatening infections require hospitalization. It is most 
prudent, initially to administer antibiotics parenterally to ensure adequate 
serumlevels. 
Principles of Surgical Management: 
¾ Early recognition and prompt intervention. 
¾ Control of blood glucose 
¾ Complete rest of injured area. 
¾ Careful but complete debridement and drainage of all involved areas. 
¾ Appropriate antibiotic coverage 
¾ Wound care and dressings 
¾ Appropriate vascular reconstructions 
¾ Careful follow up including podiatric appliances and modified footwear. 
¾ More experienced consultation as necessary. 
Wagner Grade 1 foot: These are patients with superficial ulcers and cellulitis. 
Infection is controlled with appropriate antibiotics and debridement if required. 
Ulcers occur because of repetitive pressures. Pressure is relieved by complete bed 
rest, use of total contact cast, walker, braces etc. Associated vascular insufficiency 
has to be corrected by vascular reconstruction. 
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Wagner Grade 2 and Grade 3 feet : These are patients with deep ulcers, with or 
without complications like abscesses and osteomyelitis. Aggressive surgical 
debridement, excision of the infected bone and vascular reconstruction if 
necessary is the mainstay of the treatment. To avoid recurrence education about 
foot care is essential. 
Wagner Grade 4 and 5 feet: 
These are patients with localized or extensive gangrene. Management is by 
appropriate minor or major amputation followed by vascular reconstruction. 
Local Treatment of Diabetic Foot: 
Uncontrolled diabetes affects infection and infection adversely affects 
diabetes. 
The basic rules in treating any foot infection are: 
o Absolute bed rest 
o Regulation of diabetes 
o Adequate culturing of wound 
 Administration of appropriate antibiotics 
 Adequate drainage of all infection 
 Appropriate wound care. 
Drainage: Drainage means opening all abscesses, probing carefully, and laying 
open all sinus tracts, debriding all necrotic tissue and providing unhindered 
dependent drainage of pus in the resting foot. The pus must drain down and out. 
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Gas in the tissues can often be felt as crepitus or may be the first detected on x-ray 
film. This is a serious finding and must be treated immediately by open drainage 
of all infected spaces and prompt i.v. antibiotics. 
Drainage of an infected area may involve amputation of a necrotic toe or 
toes or even an open amputation. Such amputations are drainage procedures 
primarily. The avascular joints tolerate infection badly, and ultimately the infected 
joints in the toes and the feet have to be removed. When an infected area has been 
enclosed, it is important to plan and attempt to salvage tissue for a possible 
definitive wound closure. 
Dressings: 
Most foot infections do not require extensive incisions debridement, yet the 
principles must always be remembered. Dressings are used to serve the following 
purposes. 
¾ Contain wound drainage. 
¾ Debride a wound 
¾ Protect an area from trauma 
¾ Protect an area from contamination 
¾ Promote proper wound healing  
The basic equipment necessary for bedside foot care is: 
1. Sterile debridement set containing 
¾ Sharp scissors for debriding 
¾ Blunt ended needle wound probe 
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¾ Smooth forceps 
2. Sterile toenail clippers 
3. Sterile guaze dressings 
4. Tube guage, paper tape, culture tubes 
5. Medicines - Povidone iodine 2.5% - Bactericidal 
¾ Dakin's solution (chlorazene 0.25%) 
¾ Bactracin ointment - antibacterial 
¾ Vaseline guaze 
¾ Normal saline 
Dakin's solution: is a chlorine releasing agent that is both bactericidal and active 
in loosening necrotic tissue to aid in local debridement. Dakin's also helps to 
control fetid odours from severely infected wounds. 
Open wounds require packing using an unfilled guage moistened with 
atherapeutic solution. Changing packing two or three times a day is recommended 
for debridement of a necrotic wound. Allowing sufficient time between dressing 
changes gives the packing time to begin to dry and therefore provide gentle 
debridement as the packing is removed from the wound. Unfilled guaze is 
recommended for packing wounds. Care must be taken not to pack the wound too 
tightly as it tightly obstructs drainage. 
A properly applied dressing will not constrict the foot or leg or slip, 
possibly causing wound trauma or exposure. Spiralling or wrapping the roller 
40 
 
guage in a figure of eight fashion is the best way to prevent a tourniquet effect and 
will decrease the risk of compromising the circulation of the foot. 
Routine Foot Dressings: 
o Moisten guaze with appropriate solution and pack the wound gently. 
o Fashion a heel cup from cut, folded and taped abdominal pad. 
o Fluff two 4 inch guaze sponges over toes 
o Secure the primary dressing, including heel cup by using a spiral 
roller by wrapping in a figure of eight fashion. 
o Apply paper tape to secure the roller guaze. 
Casts / Splints: 
A cast or splint may be applied to immobilize a limb after a skin graft or to 
protect the incision and reduce contractures after a below knee amputation. 
Applying a rigid plaster cast or splint to any neuropathic extremity can be 
hazardous and may cause pressure sores. 
Amputation Stump Dressings: 
The dressing applied to any amputation stump is fashioned to meet the 
needs of the wound. Since most amputation wounds do not have drains, the 
dressing is put on more for wound protection than to collect and contain blood and 
secretions. A first transmetatarsal amputation dressing is a bulky standard foot 
dressing. A posterior splint may be applied to prevent plantar flexion and thus 
avoid tension on the delicate suture line. A below knee amputation (BKA) 
requires an extra bulky initial. 
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Dressing to contain the initial expected bleeding. Below knee amputations 
are managed with a posterior splint that extends from the crease of the buttocks to 
beyond the end of the stump. A well padded knee immobilizer is the splint of 
choice. Knee flexion is a natural pain relieving action or reflex that, if allowed to 
occur, can lead to serious contracture. It is customary to have a patient with a 
BKA measured for a prosthesis on the 3rd or 4th post op day. Depending on the 
progression of stump healing, a patella bearing prosthesis may be fitted and 
patient begins mobilization eight to ten days postoperatively. 
The initial dressing for an Above Knee Amputation (AKA) is bulky and 
similar to the BKA dressing. Splints are not used for AKA despite the tendency 
for patients to hold up and flex the painful thigh. The stump usually falls down 
with muscle fatigue, thus decreasing the tendency for a hip contracture. 
Skin graft dressings are usually applied in accordance with the surgeon's 
preference. Mesh grafts are the most common split thickness skin graft. The mesh 
graft has proved to be the most successful because the open mesh allows adequate 
wound drainage. 
Bed rest is the first thing in the care of a diabetic foot lesion. Bed rest must 
be absolute and continuous. A patient with diminished circulation who has a 
painful ischemic foot lesion may be helped by having the head of the bed elevated 
to 6-8 inches. This elevation allows gravity flow of blood to the feet and is known 
as arterial position or Reverse Trendlenberg position. 
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Non-Surgical Modalities to Enhance Healing: 
1. Growth Factors 
Greater understanding of the healing process at the cellular level has 
resulted in the use of growth factors like becaplermin, recombinant platelet- 
derived growth factor, are produced through recombinant DNA technology. 
According to a study by Steed et al, debridement enhances the effectiveness of 
becapiermin in healing chronic neuropathic ulcers. 
2. Human Skin Equivalents 
Modern human skin replacement dates back to the 1960s, when advances 
in tissue culture technologies led to the cultivation of human epidermal cells. 
These were obtained via biopsy of the tissue and treated with trypsin so that the 
dermis get separated from epidermis. 
The keratinocytes were then grown in vitro to produce sheets of autologous 
epidermal tissue. These sheets were fragile, delicate to handle, and provided only 
50 percent to 60 percent permanent take. New tissue required two to three weeks 
growth time, and lacked a dermal component, vital in skin grafting. 
More dermis grafted means less wound contracture and scarring, more 
tensile strength and better cosmetic results. Refinements in the development of a 
matrix led to the development of Dermagraft, a living, metabolically active, 
immunologically inert dermal tissue. 
 
 
43 
 
Dermagraft contains normal dermal matrix proteins and cytokines, and is 
composed of cultural neonatal fibroblasts grown on a polyglycolic acid 
bioabsorbable mesh. As the tissue grows it produces extracellular proteins and 
closely resembles human skin. In two studies by Gentzkow et al and one by 
Pollak et al, patients were enrolled with full-thickness diabetic ulcers that had 
adequate perfusion. Pooled data showed that 51 percent of those who received a 
weekly application of Dermagraft for 12 weeks achieved complete healing, vs. 
31.7 percent in the control group. 
Apligraf, another living tissue equivalent, was approved by the Food and 
Drug Administration in 1998 for venous leg ulcers. Apligraf consists of bovine 
Collagen matrix containing fibroblasts and connected to a layer of stratified 
epithelium. The result is a sheet of tissue with both dermal and epidermal layers, 
metabolically and biochemically comparable to human skin. The dermoepidermal 
junction is flatter, however, and there are no melanocytes, Langerhans cells, 
lymphocyes or hair follicles present. 
In a study by Falanga et al, 293 patients with non-healing venous ulcers 
received either compression therapy or Apligraf. At six months, 63 percent of the 
patients receiving Apligraf healed vs. 49 percent in the control group and did I so 
more quickly - than the control group - 61 vs. 181 days to closure. 
3. Miscellaneous Topical Agent: 
Collagen: Collagen is critical in the proliferative phase of wound healing. 
Exogenous sources of collagen primarily purified bovine extracts, are available as 
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gels, particles, and in an alginate dressing. Exogenous collagen provides 
additional protein for tissue repair. As a foreign agent it might also revert the 
chronic wound to an inflammatory phase, "jump-starting" the healing process. 
Donaghue et al evaluated the alginate dressing (Fibracol, Johnson and 
Johnson, Arlington, Texas) in the treatment of diabetic foot ulcers. Seventy-five 
patients were randomly assigned to either a collagen-alginate dressing or gauze 
group. At the end of the study, the mean reduction in wound size was 80.6 percent 
for the collagen-alginate group and 61.1 percent for the gauze group. Complete 
healing was achieved in 48 percent of the collagen-alginate group and 36 percent 
in the gauze group. 
Hyaluronic Acid: Hyaluronic acid is involved in the structure and organization of 
the extracellular matrix and is associated with increased mitotic activity. It is a 
highmolecular weight polysaccharide synthesized in the plasma membrane of 
fibroblasts and other cells. The ability of injured fetal tissues, which are high in 
Hyaluronic acid, to heal without scarring has prompted extensive research 
Beta Glucan: It is a major cell-wall carbohydrate extracted from such grains as 
oats and barley. The biological activity of beta glucan results from its ability to 
bind macrophage beta-glucan receptors and promote macrophage stimulation. 
Beta glucan products enhance the activities of not only macrophages but 
also neutrophils, natural killer cells, T cells and B cells. Beta glucan is thought to 
increase macrophage infiltration, speeding the onset of fibroplasia and 
fibrogenesis, stimulation of increased tissue granulation, and enhanced 
reepithelialization. Beta glucan is available as either BCG matrix or Glucan II. 
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Both are available in multifilament mesh dressings; BCG matrix is also 
impregnated with collagen. 
Silver Arglaes: Silver compounds are powerful antimicrobials, useful in 
promoting healing. Arglaes is an inorganic phosphate similar to other compounds 
such as silver nitrate, silver oxide and silver chloride. It consists of fused sodium 
and calcium phosphates with small amounts of silver in the presence of water, 
these materials release free silver ions. 
4. Pharmaceuticals: 
Oxandrolone: Oxandrolone is an anabolic steroid with a high anabolic and low 
androgenic ratio, and has anticatabolic, protein-sparing properties. Exogenous 
anabolic agents clubbed with nutritional intervention can result in a threefold to 
fourfold higher rate of protein synthesis than with nutritional interventions alone. 
Demling and De Santi studied eight patients with non-healing wounds and a 10 
percent or greater loss of body weight. Nutrition was optimized over four weeks, 
without significant effect on weight gain or healing. Adding oxandrolone resulted 
in gains of approximately 4 pounds per week across 12 weeks. During this time, 
five wounds closed completely and three others were 75 percent closed. 
5. Devices 
Vacuum Assisted Closure (VAC): Argenta and Morykwas determined that 
intermittent negative pressure at 125 mmHg promoted wound healing by 
improving blood flow, granulation tissue growth rates and nutrient flow while 
reducing bacterial levels. Based on these findings, Kinetic Concepts (San 
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Antonio, Texas) developed the VAC system. The VAC consists of a wound 
dressing (a charcoal - impregnated sponge - like material) connected by tubing to 
a wound canister, with a pump that creates negative pressure. A transparent drape 
or film over the dressing establishes the seal needed to create a vacuum. The 
pump can be adjusted for various levels of intermittent or continuous pressure. 
Exudate is collected in the cainster. The VAC also is said to reduce edema.15 
Radiant Heat Bandage: Heat therapy has long been employed, especially for 
musculoskeletal conditions, but it has not been widely used as a wound healing 
modality. Heat increases local blood flow, subcutaneous oxygen tenson which 
improve healing mechanisms. In clinical studies by Santilli and Robinson on 
patients with venous leg ulcers, those who used radiant heat bandage devices 
reported significant decreases in both wound size and pain across two weeks with 
no adverse effects.16 
Topical Hyperbaric Oxygen Therapy: 
The therapy is based on achieving an atmospheric pressure of 1.02 to 1.03 
atmos, which is thought to stimulate fibroblast, growth, collagen formation 
andneoangiogenesis. This provides a lethal environment for anaerobes, often a 
normal part of the diabetic foot's flora. Topical hyperbaric oxygen is administered 
using a sealedpolyethylene bag over the affected area and administering 100 
percent oxygen to apressure between 20 and 30 mmHg. Treatments last 2 to 2 and 
a halfhours. 
In a study of Landau, 50 patients with diabetic ulcers were treated with topical 
hyperbaric therapy, alone or with a low-energy laser. On average, 25 treatments 
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were performed over three months. Forty-three of the 50 patients experienced 
resolution of their ulcers. 
Classification of Dressings: 
Wound dressings have evolved over the years on the principles of 
providing protection to wound raw surface, absorbing exudates, controlling 
infection and promoting granulation tissue formation and creating ideal 
environment for healing. 
There are two major categories in dressings: 
1. Short term application: we should replace these dressings frequently 
2. Long term or skin substitutes:  
Temporary : these are applied till complete healing. Used in partial 
thikness wounds 
Semi-Permanent : these are used till autografting. Used over full thikness 
wounds. 
They are classified as conventional, synthetic, biological, based on material 
used for preparation. Each further divided into : 
o Primary Dressing :which is in physical contact to the wound bed. 
o Secondary Dressing :primary dressings are covered with these dressings. 
o Island Dressing : at the central region there is absorbent part, adhesive part 
surrounds the central portion.  
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A. Conventional Dressings: 
Fabric materials like gauze are used, but these allows moisture to evaporate 
and dries the desiccated wound bed.Also causes exogenous bacteria to enter the 
wound. Some used paraffin soaked dressings. This also led to development of 
usage of antibacterial agents like polymixin,carbolic acid in combination with 
dressings. 
B. Synthetic Dressings: 
1. Films : these are polymer sheets with adhesive coated on one side. 
Polyurethane , polyethylene, dimethyl aminoethyl methacrylate, polytetra 
fluoroethylene are commonly used.used in superficial wounds. But causes 
accumulation of wound fluid, due to impermeability to water vapour and gases, 
and lack of absorbing capacity. Thus leading to leakage and entry of exogenous 
bacteria. 
2. Foams and sprays: Polymers of polyvinyl alcohol and polyurethane are 
converted to foam solutions and are used for dressings. They are better than film 
dressings. They provide thermal insulation and keep the surface moist. They are 
permeable to gas. They are non adherent also.  Silastic foam and lyofoam are 
examples. Spray dressings are co polymers of certain compounds, eg: hydroxyl 
vinyl chloride acetate modified maleic acid ester is polyeriesed to form Aeroplast. 
3. Composite dressings:This dressing consists of more than one layer. Durabilty 
and elasticity maintained by outer layer. And inner layer maintains the adherence. 
They are classified as:   
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a. Hydrocolloid dressings:These contain mixture of gelling agents and 
elastomeric adhesive. Commonly used absorptive agent is Carboxymethyl 
cellulose. 
b. Hydrogel sheets:these are hydrophilic polymers made into sheets of 3 
dimensional networks.polyethylene oxide, polyacrylamide and 
polyvinylpyrrolidine are usually used.used in thermal burns because of their 
cooling ability. Eg: Vigilon. 
c. Hydrogel Amorphous :they are similar to hydrogel, but there isn’t any 
crosslinking between the polymers. Collagen or complex carbohydrates are 
present in small amounts. They give moisture to dry wound eschar and also 
promotes autolytic debridement  
d. Super Absorbents : examples are Combiderm, Convatec. 
e. Gels : examples are HEMA, Hydran, Geliperm etc. 
 Above mentioned dressing are usually act as a temporary covering. In large 
burns injuries these are combined with alternative wound closure techniques. 
C. Biological Dressings: 
They are obtained naturally from tissues and are combined with collagen 
lipid and elastin in various formulations. Their main advantages over synthetic 
dressings are: 
1. Prevent dehydration of wound by restoring a water vapour barrier. 
2. Lessen heat loss by evaporation 
3. Exudative loss of protein and electrolytes are reduced. 
4. Contamination of wound by organism are prevented. 
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5. Change of dressings are less painful. 
6. Joint mobility is maintained.  
7. Wound debridment can be done. 
8. Autografting made easy by creating good granulation. 
9. Reduce the healing time and 
10. Healing quality is improved and contraction of tissues are decreased. 
Other Biological dressings which are used are allografts,embryonic 
membranes, skin of foetus/neonate, fibrin, grafts from cultured epidermis/dermal 
matrix, bovine collagen is reconstituted to films. Herterografts from pigs and dogs 
are also used. 
Cost consideration: 
In this era of globalisation, the cost of treatment of chronic conditions has a 
major role to play and chronic wound management and its financial impacts are 
very important for a surgeon. The cost effectiveness of topical sucralfate : 
o Lesser time required for wound to heal or granulate 
o Better response to defenitive treatment modalities like graftings, flaps 
etc. After removal of topical therapy 
o Low cost of the sucralfate, compared to conventional dressing material. 
Thus topical sucralfate moist dressing is found to be an efficient and cost -
effective modality for treatment of diabetic ulcers.  
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ABOUT THE DRESSING MATERIAL USED IN THIS STUDY: 
TOPICAL SUCRALFATE DRESSINGS: 
Sucralfate is an oral gastrointestinal medication primarily indicated for the 
treatment of active duodenal ulcers. Sucralfate is also used for the treatment of 
gastroesophageal reflux disease (GERD) and stress ulcers. 
Unlike the other classes of medications used for treatment of peptic ulcers, 
sucralfate is a sucrose sulfate-aluminium complex that binds to the hydrochloric 
acid in the stomach and acts like an acid buffer with cytoprotective properties. 
Sucralfate was approved by the U.S. Food and Drug Administration (FDA) in 
1981. 
CHEMICAL DATA: 
Formula: C12H54Al16O75S8 
Mol. mass: 2086.75 g/mol 
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SYSTEMATIC NAME: Hexadeca-μ-hydroxytetracosahydroxy[μ8-[1,3,4,6-
tetra-Osulfo- β-Dfructofuranosyl-α-D-glucopyranoside tetrakis(hydrogen 
sulfato)8-)]] 
hexadecaaluminum 
Sucralfate has been investigated as a treatment of small wounds like 
scratches, cracks, burns, uninfected wounds and also in large wounds like 
decubitus ulcer, diabetic ulcers and other ulcers.. 
Sucralfate covers the damaged area and act as a barrier of protection. 
It is known that in case of stomach and duodenal ulcers, sucralfate tablets 
and solutions are used for many decades. They form a protective covering over 
the damaged tissue. 
In case of venous ulcers sucralfate help in wound healing by stimulating 
EGF expression and other factors which helps in tissue repairing and 
angiogenesis. 
Mechanism Of Action: 
The action of sucralfate can now be defined by the ‘1 x 1 x 1’ mechanism 
of 
action—1) acute prevention 2)healing of chronic ulcers 3) both for chronic and 
acute protection. 
The important acute actions of sucralfate are, they maintains the flow of 
blood to the tissues and integrity of the vasculature, there by leading to quick 
repairing of superficial defects. 
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Sucralfate stimulates angiogenesis, epithelisation and formation of 
granulation tissue by binding to FGF and EGF. 
Sucralfate wound healing mechanisms may include: 
¾ Stimulation of fibroblast proliferation. 
¾ Enhancing the formation of granulation tissue. 
¾ Decreasing collagenase activity, inhibition of glucocorticoid 
activity 
¾ Direct or indirect antibacterial activity by affecting 
inflammatorycells 
¾ Neovascularization. 
The in-vitro activity of sucralfate (sucrose octa-sulphate) in suspension was 
examined against 128 strains of Gram-negative bacilli. Inhibitory activity was 
demonstrated against all isolates and bactericidal activity was demonstrated for 
68. 
Sucralfate has inhibitory and bactericidal antibacterial activity which may 
contribute to its in-vivo clinical efficacy 
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CLINICAL EXPERIENCE: 
STUDY-I 
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 22: 17-23, 
2008 17 TOPICAL TREATMENT OF CHRONIC VENOUS ULCERS 
WITH SUCRALFATE: A PLACEBO CONTROLLED RANDOMIZED 
STUDY GIOVANNI TUMINO1, LAURA MASUELLI2, ROBERTO BEI3 
LUCILLA SIMONELLI2, ALBERTO SANTORO1 AND SILVANA 
FRANCIPANE4 DEPARTMENTS OF 1SURGICAL SCIENCES, 
2EXPERIMENTAL MEDICINE, UNIVERSITY OF ROME 
This ultrastructural anaylitical study showed that topical use of SUC-LIS 
95can improve the healing the chronic venous ulcers by promoting angiogenisis 
and re-epithelisation and also by reducing the inflammatory reaction. This also 
helps increasing the wound contraction. 
 
STUDY-II 
TOPICAL USE OF SUCRALFATE CREAM IN SECOND AND THIRD 
DEGREEBURNS Anjana Banatia, Siti Roy Chowdhurya, Saswati 
Mazumderb Accepted 6 November 2000. 
Abstract 
This clinical study showed that  in second degree burns, sucralfate cream 
causes quick epithelisation of the wound area. And also showed minimal side 
effects in treating burns cases. 
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STUDY-III 
ARCHIVES OF DERMATOLOGY THE USE OF SUCRALFATE 
SUSPENSION IN THE TREATMENT OF ORAL AND GENITAL 
ULCERATION OF BEHÇET DISEASE A RANDOMIZED, PLACEBO-
CONTROLLED, DOUBLE-BLIND STUDY 
Erkan Alpsoy, MD; Hanife Er, MD; Cicek Durusoy, MD; Ertan Yilmaz, MD 
Arch Dermatol. 1999;135:529-532. 
This study showed that in case of treatment of oral and genital ulcers in 
bechets disease, there is major decrease in pain caused by the ulcer and also time 
required for healing while comparing the same with the pre-treatment period. 
 The results proves that while using sucralfate topical solution in treatment 
of bechets disease, there is effective improvement in oral and genital ulcers. It is a 
safe, easy inexpensive treatment in bechets disease. 
 
STUDY-IV 
ANTIBACTERIAL ACTIVITY OF SUCRALFATE AGAINST 
ESCHERICHIA COLI, STAPHYLOCOCCUS AUREUS AND 
PSEUDOMONAS AERUGINOSA IN BATCH AND CONTINUOUS 
CULTURE. PUBLICATION: EUR J CLIN MICROBIOL INFECT DIS 
VOLUME: 12( 11), PAGE NUMBERS: 869-71,YEAR PUBLISHED: 1993 
ABSTRACT: 
The antibacterial effect of varying concentrations of sucralfate was studied 
on Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus grown 
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in both agitated batch and continuous culture. The minimum inhibitory 
concentrations estimated with the two methods were in close agreement, ranging 
from 5 to 15 mg sucralfate/ml, concentrations easily attainable in gastric juice 
after a standard adult dose. Batch culture results indicated a dose-dependent 
effect. This study provides further evidence for an antibacterial effect by 
sucralfate against a range of species associated with respiratory tract infection in 
ventilated patients 
SIDE EFFECTS: 
The most commonly reported side effect of sucralfate is constipation. 
Some of the other possible reactions include nausea, indigestion, and bloating . 
Although most problems are minor and are generally easy to treat, serious side 
effects may also occur. 
 
  
 
 
 
 
 
 
 
 
 
 
Materials and Methods 
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METHODOLOGY 
 
Study design : Prospective Randomized comparative trial 
Source of Data :Patients with long standing diabetic ulcers (>2 weeks) 
admitted in surgery wards at Tirunelveli medical college hospital, Tirunelveli over 
a period from Jaunuary 2014 to July 2015 
Sample Size: 
100 patients 
50-patients –study group 
50-patients –control group 
Inclusion criteria 
1. Patients between 12 to 75 years of age. 
2. Duration of the diabetic ulcer more than 2 weeks. 
3. Size of ulcer less than 15 x 15 cm 
4. Patients giving consent for topical sucralfate therapy 
Exclusion criteria: 
1. Pulse less limb 
2. Immunocompromised patients 
3. Associated septicaemia and osteomyelitis. 
4. Skin malignancies 
5. Diabetic Ketoacidosis. 
6. Exposed bones, tendon 
7. Charcot joint  
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Method 
The present study was carried out in Tirunelveli medical college hospital, 
Tirunelveli for a period of one and a half year, where 100 patients with diabetic 
foot ulcer more than 2 weeks participated in the present study. Using a pretested 
and pre designed proforma the study population was randomized into either study 
group or control group using a computerized randomization chart. Out of 100, 
patients, 50 took treatment in the form of conventional normal saline dressings 
and 50 took treatment with sucralfate dressing. Off-loading of pressure from the 
affected area and no antibiotics were used in both the groups. Photographs of the 
ulcers before and after the dressings were taken, along with culture and sensitivity 
of the ulcers before and after the dressings. After undergoing a detailed clinical 
examination, and relevant investigations, the initial wound area was recorded after 
sharp debridement by Measuring length x width (ulcer should be less than 15 x 15 
cm). Both the groups were subjected to once daily dressings. The patients were 
followed up on a daily basis for a period of 3 weeks in both the groups. 
The outcome that is the area of the target ulcer was measured by 
Plannimetry using a transparent graph sheet .Results were calculated by using 
student‘t’ test. 
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DRESSING TECHNIQUE: 
After allotting the dressing with the help of Random number table 
For conventional dressing: 
The ulcer was cleaned with normal saline and saline soaked gauze piece 
was kept over the ulcer which was covered with pad and roller bandage. 
For topical sucralfate dressing: 
The ulcer was cleaned with Normal Saline. A single one gram sucralfate 
tablet was crushed and powdered and placed in Soil of sterile normal saline to 
form a suspension. Sterile gauze was soaked in the suspension and placed over the 
wound at 20mg/cm2 TBSA. 
At the end of 21 days the wounds in both the groups were inspected and 
the wounds were compared based on the following parameters. They are: 
• Rate of granulation tissue formation as percentage of ulcer surface area 
• Quality of ulcer bed 
• Present dimensions and surface area of the ulcer 
The dressings were changed everyday morning in both control and study 
groups for 21 days and appearance of healthy granulation tissue is observed and 
the final area is measured on 21st day by planimetry using a transparent graph 
sheet and subjected to statistical analysis. 
  
 
 
 
 
 
 
 
 
 
 
Observations and Results 
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RESULTS 
TABLE NO. 4.1 : AGE DISTRIBUTION 
Age Mean S.D 
CONTROL 62.28 6.94 
STUDY 58.88 10.18 
 
The mean age in the study group was 58.88 years and in the control group 
was 62.28 years 
TABLE 4.2 :SEX DISTRIBUTION 
Gender Male Female
CONTROL 31 19 
STUDY 26 24 
 
Incidence of  diabetic ulcers were more in males (57.00%) as compared 
to females (43.00%). 
TABLE 4.3 : FBS 
  
Area of 
Reduction 
    
  
  
Correlation 
coefficient 
P 
value 
  
Pearson chi square test 
FBS 0.15 0.136   
 
Mean FBS in the control group was 137.06mg/dl  and that in the study 
group was 156.96mg/dl 
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TABLE4.4: ONSET 
ONSET S T 
CONTROL 40 10 
STUDY 33 17 
 
In this study, 27.00% of the ulcers were traumatic in origin. 73.00% were 
spontaneous in origin 
AREA OF REDUCTION 
TABLE NO 4.5: SITE 
Site D P MM LM 
CONTROL 16 26 5 3 
STUDY 14 25 8 3 
 
30.00% of the patients had ulcer on the dorsal surface of the forefoot and 
13.00% had ulcers on the Medial malleoli. About 51.00% on the plantar aspect, 
and about 6.00% the lateral malleoli. 
Onset CONTROL   STUDY     
  Mean S.D Mean S.D P value 
Independent 
Sample ‘t’ 
test 
S  19.08 14.75 41.93 8.35 <0.0001
T 15.54 5.35 42.05 5.33 <0.0001
62 
 
 
Area of 
Reduction CONTROL   STUDY     
  Mean S.D Mean S.D P value 
Independent 
Sample ‘t’ test 
D 18.99 15.44 43.62 9.49 <0.0001 
P 19.95 13.77 40.75 5.63 <0.0001 
MM 10.92 2.32 42.71 9.62 <0.0001 
LM 13.81 6.75 42.5 3.63 0.003 
 
 
TABLE NO 4.6: CULTURE & SENSITIVITY –AFTER 
CONTROL STUDY
CULTURE 
+ve 
49 4 
CULTURE 
     -ve 
1 46 
 
–ve culture in 46 patients in the study group, whereas 49 patients in the 
control group still had a +ve culture. 
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TABLE NO 4.7 : AREA OF REDUCTION 
Area of Reduction Mean S.D P value 
Independent 
Sample ‘t’ 
test 
CONTROL 18.37 13.43 
<0.0001STUDY 41.97 7.41 
 
Study group had better area of reduction of 41.97% (S.D : 7.41 ) as 
compared to the control group, the mean area of reduction was 18.37%(S.D ; 
13.43). These were found to be statistically significant on independent sample T 
test (p<0.0001)  
 
TABLE NO 4.8: WEEKS FOR RECOVERY 
Weeks Mean S.D P value 
Independent 
Sample ‘t’ 
test 
CONTROL 5.36 0.59 
<0.0001STUDY 2.68 0.47 
 
The mean time taken for complete healing of the ulcers were 2.68 weeks 
in the study group as compared to 5.36 weeks in the control group 
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GRAPH NO.1 AGE DISTRIBUTION 
 
The mean age in the study group was 58.88 years and in the control group 
was 62.28 years 
 
GRAPH NO. 2 : SEX DISTRIBUTION 
 
Incidence of diabetic ulcers were more in males (57.00%) as compared to 
females (43.00%). 
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GRAPH NO. 3: ONSET 
 
 
GRAPH NO.4: SITE 
 
30.00% of the patients had ulcer on the dorsal surface of the forefoot and 
13.00% had ulcers on the Medial malleoli. About 51.00% on the plantar aspect, 
and about 6.00% the lateral malleoli. 
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GRAPH NO. 5  : CULTURE AND SENSITIVITY – AFTER 
 
 
–ve culture in 46 patients in the study group, whereas 49 patients in the control 
group still had a +ve culture. 
 
GRAPH NO.6 : WEEKS FOR RECOVERY 
 
The mean time taken for complete healing of the ulcers were 2.68 weeks 
in the study group as compared to 5.36 weeks in the control group 
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GRAPH NO. 7 AREA OF REDUCTION 
 
 
Study group had better area of reduction of 41.97% (S.D : 7.41 ) as 
compared to the control group, the mean area of reduction was 18.37%(S.D ; 
13.43). These were found to be statistically significant on independent sample T 
test (p<0.0001)  
STATISTICAL ANALYSIS 
Statistical analysis was done by using Microsoft EXCEL software and 
SPSS computer program. 
Diabetic ulcers in the study group had better mean % reduction of area  
41.97% (S.D : 7.41 ) as compared to the control group which had mean % 
reduction of area  was 18.37%(S.D ; 13.43)the difference in the mean 23.6% of  
reductionof area of the two groups where studied using independent sample T test 
was found to be significant (p<0.0001). 
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DISCUSSION 
 
An ideal dressing is every surgeon’s desire, a dressing that promotes 
chronic ulcer healing without any complications. Successful wound dressing 
should keep the wound moist and be devoid of any adverse reactions such as 
infection, maceration and allergy. 
Diabetic ulcers are chronic wounds, stuck in inflammation phase and 
shows cessation of epidermal growth. 
The present study was conducted at Tirunelveli medical college hospital, 
Tirunelveli to study the effect on diabetic ulcer healing dynamics 
In the present study it was seen that the incidence of diabetic ulcers were 
more in males (57.00%) as compared to females (43.00%). 
The second national data source, NHDS documented higher hospital rates 
in males suffering from diabetic ulcers. 
The mean age group in the study group with diabetic ulcers were 59 
years and in the control group were 62 years. 
In this study, 27.00% of the ulcers were traumatic in origin, trauma being 
the triggering factor secondary to neuropathy. 73.00% were spontaneous in origin 
secondary to blister rupture or unnoticed trivial trauma. 
About 30.00% of the patients had ulcer on the dorsal surface of the forefoot 
and 13.00% had ulcers on the Medial malleoli. About half (51.00%) on the plantar 
aspect, and about 6.00% on the lateral malleoli. 
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Study conducted by Edmonds et al in 1986, (Edmonds) showed more foot 
ulcers were on plantar and fore foot areas. Most of the diabetic foot ulcers are 
invariably shoe related and due to gait abnormalities. They can be prevented by 
appropriate sized footwear. However in our study the incidence of ulcers over the 
plantar aspect of the foot were not as high as postulated by Edmonds et al. 
In our study the culture and sensitivity of the ulcers before the 
commencement of sucralfate dressings were positive for many microorganisms. In 
the study group 18 were positive for SA, 7 patients for PM, 6 for PA, 1 patient 
showed EC.18 of them did not show any growth. In the control group 17 of them 
were positive for SA. 12 of them for PM. 4 for PA, 6 for KP and 2 of them for 
EC. 9 of the patients did not show any growth  
After sucralfate dressings were given culture obtained on the 21st day 
surprisingly showed –ve culture in 46 patients in the study group, whereas 49 
patients in the control group still had a +ve culture. This may account for the 
antimicrobial activity of Sucralfate.  
In our study it was observed that participants receiving Sucralfate dressing 
had better area of reduction of 40.87% (S.D: 5.98) as compared to the control 
group receiving only conventional dressing (normal saline dressing) in whom the 
mean area of reduction was 15.62%(S.D ; 8.51).These were found to be 
statistically significant on independent sample T test (p<0.0001)suggesting that 
Sucralfate enhances wound healing in diabetic ulcers. 
Also in the sucralfate group the mean time taken for complete healing of 
the ulcers were 2.68 weeks as compared to 5.36 weeks in the control group 
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Feasibility of this study: 
In the present study we have taken 100 patients suffering from diabetic 
footulcers (>2 weeks). Patients were taken up for study based on inclusion and 
exclusion criteria. Out of 100 patients, 50 (26 males, 24 females) were study cases 
and 50 (31males and 19 females) were control. Participants included in the study 
group were treated with Sucralfate dressing from day 01 to day 21. All 50 patients 
selected for Sucralfate treatment complied for the 21 days period of the study. The 
initial area measurement was taken on day 01 and final area measurement on day 
21 was taken on transparent sheet. 
All 50 patients selected as a control complied for the 21 days duration 
period of the study. The initial area measurement on day 01 final area 
measurement on day 21 was taken on transparent sheet. The area measurement 
was done using planimetry. 
We have applied the following formula to calculate % reduction in area of 
wound after 21 days period in both cases and control groups. 
Rate of contraction of wound after 21 days of treatment = 
(Initial area – Final Area)    X   100 
            Initial area 
We have found 18.37(S.D; 13.43) contraction of wounds in the control 
groups as compared to 41.97% (S.D:7.41 ) contraction of wounds in study group. 
Therefore, study groups have a better percentage of wound contraction as 
compared to the control group. On applying independent sample T test p<0.0001 
which is significant. 
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From our study, we can say that Sucralfate dressing therapy facilitates 
wound healing in patients suffering from diabetic ulcers. 
Limitations of our study: 
Sample size is the main limitation in our study. For statistical analysis a 
sample of 100 induviduals is enough, but for further substantiation of findings and 
revealation of variations which weren’t noticed in the present study, we may need 
to do a randomised controlled comparative study with a much larger population. 
 Various factors other than  cost of dressings can influence the cost burden 
over the patient, so it also not analysed. Sucralfate dressing wasfound to be less 
expensive  and easily available when compared to conventional moist dressings. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary 
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SUMMARY 
The incidences of DIABETIC ulcers are on the rise. 15% of all diabetics 
develop diabetic ulcers, the most common site being the sole of foot. Diabetes has 
highest risk factor associated with limb threatening ischemia. Trivial trauma 
secondary to neuropathy and distorted pedal architecture causes ulcerations. 15% 
of all diabetics develop foot ulcer. 20% of admissions in diabetics are for foot 
problems. 
Various modalities of treatment have been developed to aid faster healing 
of diabetic ulcers. Course of healing in diabetic ulcer patients is unpredictable and 
sometimes resistant to treatment. 
100 patients of diabetic ulcers were studied. They were divided into two 
groups of 50 each. 
One group received Sucralfate dressing and the control group received 
treatment in the form of conventional therapy. A comparative study was done 
between both groups regarding percentage area wound reduction. 
The mean age group in the study group with diabetic ulcers was 59 years 
and in the control group were 62 years. Males were more affected than females. 
57.00% males Vs 43.00% females. 73.00% were spontaneous in origin caused 
mainly due to blister rupture or unnoticed trivial trauma. About half (51.00%) of 
the patients had ulceron the plantar surface of the forefoot. 
All patients in the study underwent X-ray of the affected foot, patients with 
stress fractures and osteomyelitis were excluded. 
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In our study it was observed that participants receiving Sucralfate dressing 
had better area of reduction of 41.97% (S.D : 7.41 ) as compared to the control 
group receiving only conventional dressing (normal saline dressing) in whom the 
mean area of reduction was 18.37(S.D ; 13.43).These were found to be 
statistically significant on independent sample T test (p<0.0001) suggesting that 
Sucralfate enhances wound healing in diabetic ulcers. 
In our study the culture and sensitivity of the ulcers before the 
commencement of sucralfate dressings were positive for many microorganisms. 
IN the study group 18 were positive for SA,7 patients for PM, 6for PA, 1 patient 
showed EC. 18 of them did not show any growth. In the control group 17 of them 
were positive for SA. 12 of them for PM. 4 for PA, 6 for KPand 2 of them for EC. 
9 of the patients did not showany growth 
After sucralfate dressings were given culture obtained on the 21st day 
surprisingly showed –ve culture in 46 patients in the study group, whereas 49 
patients in the control group still had a +ve culture. 
This may account for the antimicrobial activity of Sucralfate. Also in the 
sucralfate group the mean time taken for complete healing of the ulcers were 2.68 
weeks as compared to 5.36 weeks in the control group. 
Increased rate of granulation tissue formation was seen in topical 
Sucralfate dressing group when compared to conventional dressing group. 
Considerable effect on bacterial load was seen with the topical Sucralfate 
compared to conventional dressing group. 
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Shorter duration of hospital stay was observed in the topical Sucralfate 
dressing group.  
Topical Sucralfate dressing appears to be the main therapeutic agent in 
wound healing which is effective, inexpensive and easily available 
Thus, Sucralfate dressing therapy in the treatment of  DIABETIC ulcers 
was found to be more effective, safe, promoter of wound healing, and hence can 
be recommended for the treatment of  DIABETIC ulcers as an adjuvant to the 
conventional mode of treatment, reducing the progression of the pathology and 
hence the amputation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion 
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CONCLUSION 
 
The wounds in subjects treated with Sucralfate dressing contracted more 
than the wounds in the control group (41.97% Vs 18.37% ;                      
P = < 0.0001ÆSignificant) which indicates Sucralfate dressing is an effective 
modality to FACILITATE area of reduction of wound in patients suffering from 
DIABETIC footulcers and can be used as an adjunct to conventional mode of 
treatment (conventional dressings and debridement) for faster and better healing 
of DIABETIC ulcers. 
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ANNEXURE-II 
RESEARCH PARTICIPANT INFORMATION AND CONSENT FORM 
Mr. /Miss/ Mrs. _____________________ 
You are invited to participate in our research study that is “A CLINICAL 
STUDY OF COMPARISION BETWEEN EFFICACY OF TOPICAL 
SUCRALFATE AND CONVENTIONAL DRESSING IN THE 
MANAGMENT OF DIABETIC ULCER” 
Since you are suffering from Diabetic ulcer, which is not healing since a 
long time and will be requiring treatment for the same, you are eligible to be part 
of the study and hence asked to participate. This research is about the beneficial 
effects of Sucralfate dressing therapy on your foot ulcer and the result of this 
research will help in a better treatment of similar participants in the future. 
If you agree to be a part of this research, we would ask you some relevant 
clinical history. You are free to not to answer to whichever question u think are 
not relevant. Aclinical examination will be done and then you will be treated with 
either Sucralfate dressing therapy or the normal saline dressing for 21 days. On 
the first day the area of the ulcer will be measured and this will be repeated at the 
end of the therapy that is21stday. Also culture and sensitivity, and photographs of 
the ulcers before and after the dressings will be taken. There are chances you may 
have a speedy and better recovery with this therapy and it will also help in the 
treatment of participants with similar complaints in the future. 
 
  
 
 
Your decision of whether or not to participate in this study will not affect the 
quality of treatment you receive. Further you may withdraw from the study at any 
time. 
All the new information collected about you during the course of this study 
will be kept confidential to the extent permitted by the law. Any information, 
which identifies you personally, will not be released without your written consent 
This study does not have any damaging aspect and there are no chances of 
injury during the course of the study, but if injured the investigator is not 
responsible. There will be extra cost incurred by you. However you will have to 
pay for the routine investigations, which are a part of the existing management 
protocol for the treatment of ulcers, and diabetes. There is no commitment for any 
reimbursement or any compensation for the participant. The participation in this 
study is entirely voluntary and you may withdraw from the study at any time. At 
any time during or after the study, for any information you may contact the 
researcher. 
Dr.John Amalan.A 
P.G hostel, Room no: 19 
Tirunelveli medical college hospital 
High ground, Tirunelveli, Tamilnadu. 
 
Signature of the participant or legally authorized representative: 
Place : ____________________ 
Participant’s name ___________________________________ 
Signature :___________________________________ 
Experimenter/witness’s Name :___________________________________ 
Signature : ___________________Date :____________________ 
 
 
ANNEXURE-III 
PROFORMA 
I) PATIENT IDENTIFICATION DATA : 
NAME IP/OPD NO. 
AGE DOA : 
SEX DOD: 
OCCUPATION 
ADDRESS 
II) CHIEF COMPLAINTS : 
MEDICAL HISTORY : 
Peripheral Neuropathy :  ( ) 
Nephropathy    ( ) 
Retinopathy    ( ) 
PVD     ( ) 
CVD     ( ) 
DIABETIC STATUS : 
TYPE : 
DURATION : 
MEDICATION : Oral Hypoglycemics Insulin 
( )   ( ) 
COMPLICATION Neuropathy  ( )Vasculopathy   ( )   
 
 
ULCER DETAIL : 
1. Mode of onset 
Traumatic    ( ) 
Spontaneous    ( ) 
Pressure    ( ) 
Others     ( ) 
2. Duration 
3. Progress 
WOUND OBSERVATION: 
1. Site 
2. Size 
3. Shape 
4. Edge 
5. Margin 
6. Floor 
7. Base 
8. Discharge 
9. Surrounding Skin 
10. Contractor 
NERUROLOGICAL EXAMINATION: 
VASCULAR EXAMINATION   Left   Right 
Popliteal a.     ( )   ( ) 
Ant . Tibial      ( )   ( ) 
 
 
Post Tibial      ( )   ( ) 
Dorsalis Pedis     ( )   ( ) 
ANY FOOT DEFORMITY PRESENT: 
Toe deformity 
Bunion 
Charcots joint 
Foot drop 
IF AMPUTATION HAS BEEN DONE 
SPECIFY  : Date 
: Side 
: Level 
: Cause for amputation 
FOOT WEAR ASSESSMENT: 
Does patient wear appropriate shoes 
Does patient require contact cast immobilization. 
INVESTIGATIONS. 
CBC 
FBS 1st _________________ Date :________ Time :_________ 
2nd (24 hr apart ) ___________ Date :________ Time : _________ 
Sr. Creatinine 
UKB 
Urine : Routine 
Microscopy 
 
 
X-ray Foot 
AP View 
Lat. View 
Wound C/s 
WOUND AREA MEASUREMENT ON D1 in mm2 
Type of Dressing –   saline dressing   ( ) 
-     Sucralfate dressing   ( ) 
 
  
 
 
Key for using the master sheet: 
Sl.no  :  Serial number 
M  :  Male 
F  :  Female 
FBS  :  Fasting Blood Sugar 
C/s (A)  :  Culture sensitivity report After sucralfate dressing 
C/s (B)  :  Culture sensitivity report Before sucralfate dressing 
mm2  :  millimetre square 
T  :  Traumatic 
S  :  Spontaneous 
D  :  Dorsal 
P  :  Plantar 
MM  :  Medial Malleoli 
LM  :  Lateral malleoli 
NOGC  :  No Organisms Grown in Culture 
SA  :  Staphylococcus Aureus 
KP  :  Klebsiella Pneumonia 
PM  :  Proteus Mirabilis 
PA  :  Pseudomonas Aeruginosa 
EC  :  Eischericia Coli 
MASTER CHART 
Control Group 
SL 
NO 
NAME AGE SEX ONSET SITE FBS XRAY 
C/S 
before 
C/S 
after 
INITIAL 
AREA in 
mm2 
FINAL 
AREA in 
mm2 
IA-FA = CA 
(controlled 
area) mm2 
AREA OF 
REDUCTION in % 
WEEKS FOR 
COMPLETE 
HEALING 
1 ANDI 60 M S P 104 N PM POS 3187.09 2780.73 406.36 12.75 4 
2 SOOSAIYAMMAL 63 F S P 109 N SA POS 1925.77 1561.63 364.14 18.9 5 
3 KOVILPILLAI 48 M S P 206 N SA POS 1948.87 1662.90 285.96 14.6 5 
4 MAHAKALI 82 M S P 302 N NOGC NEG 3117.32 1766.06 1551.33 46.7 5 
5 KUMARAPPAN 78 M T P 108 N NOGC NEG 3536.87 2991.73 545.14 15.4 5 
6 SUBBAIAH 64 M T P 124 N NOGC NEG 3147.49 2283.48 864.01 27.4 5 
7 SHAHUL HAMEED 63 M S P 126 N PM POS 3428.93 2887.52 541.40 15.7 6 
8 LAKSHMI 78 F S D 132 N PA POS 3473.83 2961.90 511.92 14.7 6 
9 AGNIMUTHU 64 M S D 108 N PA POS 2763.83 2402.70 361.12 13.06 6 
10 MADASAMY 55 M S MM 204 N SA POS 2265.74 1939.14 326.60 14.4 5 
11 KALIMUTHU 58 M S LL 111 N PM POS 3456.65 3132.76 332.88 9.63 6 
12 RAMALAKSHMI 62 F S LL 132 N NOGC POS 3226.56 2895.51 331.04 10.2 6 
13 RAJENDRAN 66 M S MM 104 N NOGC POS 2436.79 2163.10 273.69 11.2 5 
14 CHELLADURAI 62 M S D 96 N NOGC NEG 2663.75 2228.39 435.36 16.3 4 
15 GANESH 63 M T P 98 N NOGC NEG 2893.00 2619.32 273.67 9.4 5 
16 KANAGAVALLI 59 F T P 93 N PM POS 2693.85 2402.70 291.14 10.8 6 
17 THANGALAKSHMI 62 F T P 88 N SA POS 3365.95 2875.51 490.43 14.57 6 
18 RAJAKANI 66 F S P 116 N SA POS 3564.98 3217.03 347.94 9.76 5 
19 SHEEBAMUTHAMA 60 F S P 128 N SA POS 1344.99 1153.01 191.98 14.2 5 
20 BHASKAR 68 M S P 122 N SA POS 2535.55 2271.88 263.67 10.3 4 
21 ISAKKI 80 M S P 204 N SA POS 3547.20 3078.67 468.52 13.2 6 
22 MUTHU 80 M S P 222 N EC POS 2673.99 2360.06 313.90 11.7 5 
23 ARUMUGHAN 54 M S D 168 N PM POS 3134.45 2845.14 289.30 9.23 6 
SL 
NO 
NAME AGE SEX ONSET SITE FBS XRAY 
C/S 
before 
C/S 
after 
INITIAL 
AREA in 
mm2 
FINAL 
AREA in 
mm2 
IA-FA = CA 
(controlled 
area) mm2 
AREA OF 
REDUCTION in % 
WEEKS FOR 
COMPLETE 
HEALING 
24 THAIYAMMAL 68 F T D 108 N PM POS 1425.78 1201.91 223.80 15.7 5 
25 PITCHAIMUTHU 60 M S D 137 N PM POS 2918.10 2590.72 327.29 11.2 6 
26 MALATHI 58 F S P 126 N KP POS 2973.09 2281.36 691.73 23.26 6 
27 ANDINACHI 54 F S D 131 N SA POS 1783.06 683.04 1100.02 61.69 6 
28 PALANIGURU 62 M S P 144 N KP POS 1436.08 736.04 700.04 49.08 6 
29 VELLAIYAPPAN 70 M S P 156 N PM POS 1536.21 526.02 1010.01 65.74 6 
30 SOMASUNDARAM 49 M S MM 142 N PM POS 3426.77 3086.11 340.66 9.94 6 
31 NAGARAJAN 53 M S P 160 N PM POS 3034.45 2645.15 389.30 12.8 5 
32 NATARAJ 56 M S D 172 N SA POS 2473.43 2261.11 222.00 8.57 6 
33 MARIYAMMAL 62 F S D 208 N NOGC NEG 3427.26 2991.67 435.58 12.7 5 
34 ANNAPUSHPAM 66 F S D 214 N EC POS 2439.11 2071.82 367.28 15.05 5 
35 ARUMUGADEVAR 68 M T P 164 N SA POS 922.09 723.01 199.08 21.5 5 
36 VELAYUDHAM 72 M T P 206 N SA POS 3555.91 3017.11 538.79 15.1 5 
37 MARICHAMI 48 M S P 168 N PA POS 2592.82 2202.72 390.09 15.0 5 
38 ISMAIL 70 M S P 102 N KP POS 2881.99 2419.32 462.66 16.05 6 
39 AKHILA 64 F S D 134 N PA POS 2552.75 2221.49 331.26 12.9 5 
40 AMBUJAM 63 F S D 138 N SA POS 2310.73 2078.66 232.06 10.0 5 
41 NELLAIYAPPAN 54 M S S 144  N PM POS 2236.72 2063.99 172.73 7.7 6 
42 PATTIVEERAN 55 M S MM 128 N PM POS 3026.36 2691.31 335.04 11.07 5 
43 SAROJA 59 F S MM 110 N KP POS 3056.69 2811.71 244.98 8.0 6 
44 PALAVESAM 62 F S LL 107 N SA POS 2199.72 1722.60 477.11 21.6 6 
45 CHINNATHAI 53 F S P 68 N SA POS 2211.83 1902.11 309.71 14.0 5 
46 NAFISABEEVI 64 F T D 96 N SA POS 2999.11 2561.9 437.21 14.5 5 
47 SOORIYAN 62 M T P 102 N NOGC POS 3011.91 2675.52 336.38 11.1 5 
48 PETCHIKUTTY 72 F S D 88 N KP POS 3083.40 2140.11 943.29 30.5 5 
49 CHANDRAN 65 M S P 95 N SA POS 5336.81 3741.73 1595.07 29.8 5 
50 ABRAHAM 60 M S D 100 N KP POS 3015.70 1504.01 1511.69 50.1 6 
Study Group 
SL 
NO 
NAME AGE SEX ONSET SITE 
FBS 
(mg/dl)
XRAY
C/S 
(before) 
C/S 
(after) 
INITIAL 
AREA in 
mm2 
FINAL 
AREA in 
mm2 
IA-FA = CA 
(controlled 
area) mm2 
AREA OF 
REDUCTION 
in % 
WEEKS FOR 
COMPLETE 
HEALING 
1 palanisamy 50 m S D 132 N NOGC NEG 1496.05 436.02 1060.03 70.8 2 
2 MARIYAMMAL 60 F S D 108 N NOGC NEG 1386.60 642.40 744.20 53.6 2 
3 PARVATHY 55 F S P 164 N SA NEG 2292.05 1122.89 1169.15 51.0 2 
4 MURUGAN 49 M S P 134 N PM NEG 3181.93 2060.76 1121.17 35.2 2 
5 MARIYAPPAN 46 M T P 150 N SA NEG 2192.00 1322.87 869.12 39.6 3 
6 VELU 70 M S MM 120 N NOGC NEG 1090.55 432.22 658.33 60.3 3 
7 SHANMUGAM 65 M S D 137 N NOGC NEG 2735.65 1656.43 1079.22 39.4 3 
8 SANKARAYYAH 55 M S D 162 N SA  NEG 1563.08 942.36 620.71 39.7 3 
9 PETCHIAPPAN 62 M S MM 155 N SA NEG 2536.97 1625.69 911.28 35.9 3 
10 MUTHAMMAL 70 F T MM 150 N  SA  NEG 1535.73 989.14 546.59 35.5 3 
11 NATHAN 48 M T D 140 N  SA  NEG 1432.38 881.68 550.70 38.4 3 
12 KUMARASAMY 49 M T D 160 N NOGC NEG 2293.00 1122.82 1170.18 51.0 2 
13 MURUGATHAL 55 F  S  D 142 N PM NEG 3191.83 2067.93 1123.90 35.2 3 
14 SAMY 56 M S MM 128 N NOGC NEG 2392.00 1422.87 969.12 40.5 3 
15 PAPATHI 62 F T MM 108 N NOGC NEG 1191.66 532.22 659.44 55.3 3 
16 YAGAMMAL 48 F S P 239 N PM NEG 2835.65 1756.43 1079.21 38.05 3 
17 MUNIYAPPAN 82 M S P 202 N PM NEG 1633.08 1042.36 620.71 37.32 3 
18 PAPPA 77 F S P 196 N SA NEG 2537.9 1725.69 812.28 32.0 3 
19 MARIMUTHU 60 M T LL 132 N SA NEG 3233.13 1923.00 1310.13 40.5 3 
20 SATYAMOORTHI 48 M T MM 204 N SA NEG 3563.00 2110.00 1453.00 40.7 3 
21 KALIYAMMAL 38 F S D 302 N SA NEG 3543.93 2293.45 1250.40 35.28 3 
22 MUTHUMARI 46 F S P 226 N NOGC NEG 2369.83 1372.29 997.53 42.09 3 
23 CHITRA 44 F T P 138 N PM NEG 3487.83 2108.77 1379.08 39.54 3 
24 CHELAMMAL 49 F T P 104 N PA NEG 3425.44 1971.57 1453.87 42.4 2 
25 MUTHUKANI 60 F S D 324 N EC NEG 2194.93 1241.01 953.91 43.4 3 
SL 
NO 
NAME AGE SEX ONSET SITE FBS XRAY
C/S 
(before) 
C/S 
(after) 
INITIAL 
AREA in 
mm2 
FINAL 
AREA in 
mm2 
IA-FA = CA 
(controlled 
area) mm2 
AREA OF 
REDUCTION 
in % 
WEEKS FOR 
COMPLETE 
HEALING 
26 MANI 72 M S P 168 N PA NEG 2425.62 1393.67 1031.95 42.5 2 
27 PALPANDI 86 M S P 148 N SA NEG 3333.13 2023.00 1310.13 39.3 2 
28 BOOPALAN 80 M S P 136 N NOGC NEG 3663.10 2110.10 1553.0 42.3 3 
29 VELDURAI 76 M S MM 222 N NOGC NEG 3698.93 2373.45 1325.47 35.8 3 
30 KANNIYAPPAN 62 M S LL 201 N NOGC NEG 2399.83 1432.27 967.53 40.3 3 
31 KANAGA 40 F S D 186 N PM NEG 3587.83 2208.74 1379.08 38.4 3 
32 DURAICHI 39 F S D 232 N PA NEG 3429.82 1871.59 1558.22 45.4 3 
33 SANTHAPERUMAL 64 M T P 106 N PA NEG 2174.93 1242.01 932.92 42.8 3 
34 ANTONY 49 M T P 96 N PA NEG 2392.63 1293.67 1098.96 45.9 3 
35 SAKUNTHALA 63 F S P 108 N PA NEG 3546.63 1493.67 2052.96 57.88 2 
36 KAMALAM 64 F S P 92 N SA NEG 2533.94 1598.00 935.94 36.93 3 
37 MUTHUVELPANDIYAN 74 M T P 106 N NOGC NEG 2533.76 1617.93 915.83 36.14 3 
38 KARUPAPILLAI 62 M T P 108 N SA NEG 3316.07 1829.88 1486.18 44.81 3 
39 NAGAMMAL 69 F S P 138 N NOGC NEG 2532.84 1440.97 1091.87 43.1 3 
40 SELVIMARY 59 F S P 142 N SA NEG 3331.93 2101.91 1230.02 36.9 2 
41 FATHIMA 60 F T P 165 N NOGC NEG 2636.84 1692.39 944.44 35.8 2 
42 NOORNIZA 62 F S P 138 N NOGC NEG 1635.73 990.23 645.49 39.4 3 
43 SAMYMUTHU 48 M S MM 154 N NOGC NEG 3231.93 2010.91 1221.02 37.7 2 
43 PECHITHAI 64 F S LL 172 N NOGC NEG 2535.83 1350.19 1185.63 46.7 3 
44 KANNIYAMMAL 65 F T P 229 N PM NEG 3216.07 1739.28 1476.79 45.91 3 
45 KESAVAN 61 M T D 109 N SA NEG 2423.95 1498.09 925.86 38.1 3 
46 AMUDA 70 F T D 136 N SA NEG 2425.62 1393.67 1031.95 42.5 2 
47 ULAGATHAL 68 F S D 201 N SA NEG 3487.83 2108.74 1379.08 39.5 2 
48 THIRUPATHI 55 M S P 106 N SA NEG 2550.02 1550.00 1000.02 39.2 2 
49 PALANI 60 M S P 92 N NOGC NEG 1896.04 1294.04 602.0 32.7 2 
50 ARUCHAMI 55 M S D 104 N NOGC NEG 2290.05 1120.89 1169.15 51.0 3 
 
